Skip to main content

Advertisement

Log in

Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?

  • Review Article
  • Published:
HSS Journal

Abstract

Pathologic conditions resulting from excessive bone destruction include osteoporosis, rheumatoid arthritis, metastases, periprosthetic osteolysis, cherubism, and others. A scarcity of molecular targets in bone has thwarted the development of drugs to combat these conditions. Nuclear factor of activated T-cells (NFAT) is a master regulator of osteoclastogenesis and is induced by RANKL. The immunosuppressive drugs, Cyclosporin A and Tacrolimus, inhibit osteoclast formation by targeting the NFAT/calcineurin pathway. These NFAT inhibitors should be considered in the treatment of osteoclastic hyper-resorptive syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Day CJ, Kim MS, Lopez CM et al (2005) NFAT expression in human osteoclasts. J. Cell Biochem 95(1):17–23

    Article  PubMed  CAS  Google Scholar 

  2. Lietman SA, Yin L, Levine MA (2008) SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem. Biophys. Res. Commun 371(4):644–648

    Article  PubMed  CAS  Google Scholar 

  3. Clipstone NA, Crabtree GR (1992) Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357(6380):695–697

    Article  PubMed  CAS  Google Scholar 

  4. Beals CR, Clipstone NA, Ho SN et al (1997) Nuclear localization of NFATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev 11(7):824–834

    Article  PubMed  CAS  Google Scholar 

  5. Takayanagi H, Kim S, Koga T et al (2002) Induction and activation of the transcription factor NFATc1(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3:889–901

    Article  PubMed  CAS  Google Scholar 

  6. Hirotani H, Tuohy NA, Woo JT et al (2004) The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem 279(14):13984–13992

    Article  PubMed  CAS  Google Scholar 

  7. Asagiri M, Sato K, Usami T et al (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med 202:1261–1269

    Article  PubMed  CAS  Google Scholar 

  8. Ishida N, Hayashi K, Hoshijima M et al (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem 277(43):41147–41156

    Article  PubMed  CAS  Google Scholar 

  9. Komarova SV, Pereverzev A, Shum JW et al (2005) Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc. Natl. Acad. Sci. U S A 102(7):2643–2648

    Article  PubMed  CAS  Google Scholar 

  10. Yeo H, Beck LH, Thompson SR et al (2007) Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J. Biol. Chem 282(48):35318–35327

    Article  PubMed  CAS  Google Scholar 

  11. Sun L, Peng Y, Zaidi N et al (2007) Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am. J. Physiol. Renal Physiol 292(1):F285–F291

    Article  PubMed  CAS  Google Scholar 

  12. Kino T, Hatanaka H, Hashimoto M et al (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. 1. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40(9):1249–1255

    CAS  Google Scholar 

  13. Miyazaki M, Fujikawa Y, Takita C et al (2007) Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun orMITF in rheumatoid arthritis. Clin. Rheumatol 26(2):231–239

    Article  PubMed  Google Scholar 

  14. Timmerman LA, Clipstone NA, Ho SN et al (1996) Rapid shuttling of NFAT in discrimination of Ca2+ signals and immunosuppression. Nature 383:837–840

    Article  PubMed  CAS  Google Scholar 

  15. Day CJ, Kim MS, Stephens SRJ et al (2004) Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J. Cell Biochem 91:303–315

    Article  PubMed  CAS  Google Scholar 

  16. Epstein S, Shane E, Bilezikian JP (1995) Organ transplantation and osteoporosis. Curr. Opin. Rheumatol 7(3):255–261

    Article  PubMed  CAS  Google Scholar 

  17. Yamanaka Y, Abu-Amer W, Foglia D et al (2008) NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis. J. Orthop. Res 26(12):1577–1584

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark S. McMahon MD.

Additional information

The author certifies that he has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McMahon, M.S. Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?. HSS Jrnl 5, 159–160 (2009). https://doi.org/10.1007/s11420-009-9115-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11420-009-9115-x

Keywords

Navigation